Literature DB >> 15180835

Prospective randomized evaluation of diode-laser and cryotherapy in prethreshold retinopathy of prematurity.

Raj Vardhan Azad1, Laxminarayana Pasumala, Harsh Kumar, Dinesh Talwar, Raj Pal, Vinod Kumar Paul, Parijat Chandra.   

Abstract

PURPOSE: To study the efficacy of indirect diode laser photocoagulation and cryotherapy in prethreshold retinopathy of prematurity (ROP).
METHODS: Thirty-six eyes of 18 premature infants less than 34 weeks gestational age and/or less than 1600 g birth weight with prethreshold ROP were prospectively randomized to treatment with either indirect laser photocoagulation or cryotherapy. Prethreshold ROP was defined as any stage of ROP in zone I with plus disease; or stage 3 with three or more contiguous clock hours or five or more total clock hours of involvement of retina in zone II with plus disease but less than threshold disease. Regression of the ROP was assessed for a minimum period of 6 months.
RESULTS: Regression of ROP occurred in all 36 eyes (100%) in both groups.
CONCLUSIONS: Excellent results are achieved if ROP is treated at the prethreshold stage with both indirect laser photocoagulation and cryotherapy. Although laser has definite advantages, cryotherapy can be considered as an alternative modality of treatment in developing countries due to economic reasons.

Entities:  

Mesh:

Year:  2004        PMID: 15180835     DOI: 10.1111/j.1442-9071.2004.00812.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  2 in total

Review 1.  Prevention of blindness due to retinopathy of prematurity: a national movement.

Authors:  Rajvardhan Azad
Journal:  Indian J Pediatr       Date:  2014-05-04       Impact factor: 1.967

2.  Technical aspects of laser treatment for acute retinopathy of prematurity under topical anesthesia.

Authors:  Subhadra Jalali; Rajvardhan Azad; Hemant Singh Trehan; Mangat Ram Dogra; Lingam Gopal; Venkatapathy Narendran
Journal:  Indian J Ophthalmol       Date:  2010 Nov-Dec       Impact factor: 1.848

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.